Investments
228Portfolio Exits
53Funds
9Partners & Customers
1Service Providers
1About 5AM Ventures
5AM Ventures is a seed and early-stage venture capital firm focused on building life science companies. 5AM Ventures was founded in 2002 and is based in San Francisco, California.
Latest 5AM Ventures News
Nov 14, 2023
Nouscom , a Basel, Switzerland-based clinical stage immuno-oncology company, raised €67.5M in Series C funding. The round was led by Andera Partners, Bpifrance (through its InnoBio 2 fund) and M Ventures, with participation from Revelation Partners, Indaco Venture Partners, Panakès Partners, XGen Ventures, and existing investors 5AM Ventures, EQT Life Sciences and Versant Ventures. Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors. The company intends to use the funds to continue advancing and expanding its wholly owned clinical pipeline to achieve multiple clinical value catalysts, including: Readout from its ongoing randomized Phase 2 clinical trial for NOUS-209, an off-the-shelf vaccine targeting 209 shared neoantigens, in combination with pembrolizumab for the treatment of Mismatch Repair/Microsatellite Instable (dMMR/MSI) Metastatic Colorectal Cancer (mCRC). Final readout from the ongoing Phase 1b study and advancement of NOUS-209 monotherapy in Lynch Syndrome (LS) carriers investigating the potential to intercept, prevent or delay cancer before it occurs. LS carriers have a genetic predisposition to and consequently higher risk of developing certain cancers. Promising initial results from this study were reported in a Late-breaking Abstract at the recent Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting. Completion of a Phase 1b study evaluating NOUS-PEV, a personalized cancer immunotherapy, in combination with a checkpoint inhibitor in patients with advanced melanoma and entry into randomized Phase 2 trials in indications with high unmet medical needs. Led by CEO Marina Udier, Nouscom is a clinical-stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies. Its proprietary viral vector platform has the capacity to encode for large payloads of neoantigens or other immunomodulators and clinically demonstrated to safely and potently of the immune system. Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms sponsored by Janssen Research & Development and Bristol Myers Squibb. FinSMEs 14/11/2023
5AM Ventures Investments
228 Investments
5AM Ventures has made 228 investments. Their latest investment was in Nouscom as part of their Series C on November 11, 2023.

5AM Ventures Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
11/14/2023 | Series C | Nouscom | $72M | No | Andera Partners, Bpifrance, EQT Life Sciences, Indaco Venture Partners, M Ventures, Panakes Partners, Revelation Partners, Undisclosed Investors, Versant Ventures, and XGEN Venture | 3 |
10/5/2023 | Series A | Precede Biosciences | $57M | No | 2 | |
9/13/2023 | Seed VC | Nvelop Therapeutics | Yes | Atlas Venture, F-Prime Capital, Newpath Partners, and Undisclosed Investors | 3 | |
8/21/2023 | PIPE | |||||
8/14/2023 | Series A - II |
Date | 11/14/2023 | 10/5/2023 | 9/13/2023 | 8/21/2023 | 8/14/2023 |
---|---|---|---|---|---|
Round | Series C | Series A | Seed VC | PIPE | Series A - II |
Company | Nouscom | Precede Biosciences | Nvelop Therapeutics | ||
Amount | $72M | $57M | |||
New? | No | No | Yes | ||
Co-Investors | Andera Partners, Bpifrance, EQT Life Sciences, Indaco Venture Partners, M Ventures, Panakes Partners, Revelation Partners, Undisclosed Investors, Versant Ventures, and XGEN Venture | Atlas Venture, F-Prime Capital, Newpath Partners, and Undisclosed Investors | |||
Sources | 3 | 2 | 3 |
5AM Ventures Portfolio Exits
53 Portfolio Exits
5AM Ventures has 53 portfolio exits. Their latest portfolio exit was Dianthus Therapeutics on September 11, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
9/11/2023 | Reverse Merger | 4 | |||
8/21/2023 | Acquired | 2 | |||
7/18/2023 | IPO | Public | 4 | ||
Date | 9/11/2023 | 8/21/2023 | 7/18/2023 | ||
---|---|---|---|---|---|
Exit | Reverse Merger | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 4 | 2 | 4 |
5AM Ventures Acquisitions
1 Acquisition
5AM Ventures acquired 1 company. Their latest acquisition was Borean Pharma on January 15, 2008.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
1/15/2008 | Series B | $18.46M | Asset Sale | 1 |
Date | 1/15/2008 |
---|---|
Investment Stage | Series B |
Companies | |
Valuation | |
Total Funding | $18.46M |
Note | Asset Sale |
Sources | 1 |
5AM Ventures Fund History
9 Fund Histories
5AM Ventures has 9 funds, including 5AM Ventures VII.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
4/4/2022 | 5AM Ventures VII | $450M | 1 | ||
4/4/2022 | 5AM Opportunities II | ||||
2/13/2019 | 5AM Ventures VI | ||||
2/13/2019 | 5AM Opportunities I | ||||
5/27/2016 | 5AM Ventures V |
Closing Date | 4/4/2022 | 4/4/2022 | 2/13/2019 | 2/13/2019 | 5/27/2016 |
---|---|---|---|---|---|
Fund | 5AM Ventures VII | 5AM Opportunities II | 5AM Ventures VI | 5AM Opportunities I | 5AM Ventures V |
Fund Type | |||||
Status | |||||
Amount | $450M | ||||
Sources | 1 |
5AM Ventures Partners & Customers
1 Partners and customers
5AM Ventures has 1 strategic partners and customers. 5AM Ventures recently partnered with Scientist.com on June 6, 2019.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
6/2/2019 | Partner | United States | Scientist.com Partners With 5AM Ventures to Create an R&D Marketplace for Biotech Startups SAN DIEGO -- -- Scientist.com , the world 's largest marketplace for outsourced R&D services , today announced a partnership with 5AM Ventures , a leading venture capital firm focused on building next-generation life science companies . | 1 |
Date | 6/2/2019 |
---|---|
Type | Partner |
Business Partner | |
Country | United States |
News Snippet | Scientist.com Partners With 5AM Ventures to Create an R&D Marketplace for Biotech Startups SAN DIEGO -- -- Scientist.com , the world 's largest marketplace for outsourced R&D services , today announced a partnership with 5AM Ventures , a leading venture capital firm focused on building next-generation life science companies . |
Sources | 1 |
5AM Ventures Service Providers
1 Service Provider
5AM Ventures has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Counsel | General Counsel |
Service Provider | |
---|---|
Associated Rounds | |
Provider Type | Counsel |
Service Type | General Counsel |
Partnership data by VentureSource
5AM Ventures Team
15 Team Members
5AM Ventures has 15 team members, including current Founder, Managing Partner, Andrew J. Schwab.
Name | Work History | Title | Status |
---|---|---|---|
Andrew J. Schwab | Bay City Capital, Montgomery, and Aravis Ventures | Founder, Managing Partner | Current |
Name | Andrew J. Schwab | ||||
---|---|---|---|---|---|
Work History | Bay City Capital, Montgomery, and Aravis Ventures | ||||
Title | Founder, Managing Partner | ||||
Status | Current |
Loading...